Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$21.03 +1.3%	$18.04	$13.53 ▼ $35.25	$2.11B	2.07	1.57 million shs	2.93 million shs
IRON Disc Medicine	$59.38 +2.8%	$51.32	$30.82 ▼ $68.73	$2.06B	0.76	343,456 shs	554,664 shs
MREO Mereo BioPharma Group	$1.71 -3.4%	$2.46	$1.57 ▼ $5.02	$271.89M	0.46	1.36 million shs	2.96 million shs
TARS Tarsus Pharmaceuticals	$42.18 -2.5%	$41.85	$20.08 ▼ $57.28	$1.77B	0.8	688,019 shs	636,154 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-1.94%	+23.81%	+13.76%	-20.01%
IRON Disc Medicine	0.00%	+1.51%	+11.94%	+37.35%	+27.25%
MREO Mereo BioPharma Group	0.00%	+9.94%	-37.89%	-24.03%	-54.38%
TARS Tarsus Pharmaceuticals	0.00%	+10.39%	+6.40%	-10.84%	+59.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.014 of 5 stars	3.5	0.0	2.1	2.5	0.6
IRON Disc Medicine	3.3623 of 5 stars	4.5	2.0	3.0	2.5	0.0
MREO Mereo BioPharma Group	1.8376 of 5 stars	3.6	1.0	2.3	1.7	0.0
TARS Tarsus Pharmaceuticals	1.4791 of 5 stars	3.5	0.0	1.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	131.81% Upside
IRON Disc Medicine	3.08	Buy	$95.73	61.21% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	321.05% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	58.05% Upside

Current Analyst Ratings Breakdown

Latest MREO, IRON, TARS, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	33.29	N/A	N/A	$8.86 per share	2.37
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
MREO Mereo BioPharma Group	$10M	27.19	N/A	N/A	$0.39 per share	4.38
TARS Tarsus Pharmaceuticals	$182.95M	9.69	N/A	N/A	$5.87 per share	7.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest MREO, IRON, TARS, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IRON Disc Medicine	-$1.17	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.41	N/A	N/A	N/A	$95.81 million	N/A
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
IRON Disc Medicine	0.04	37.65	37.65
MREO Mereo BioPharma Group	N/A	8.92	8.92
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
IRON Disc Medicine	83.70%
MREO Mereo BioPharma Group	62.83%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
IRON Disc Medicine	4.24%
MREO Mereo BioPharma Group	5.50%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

MREO, IRON, TARS, and BEAM Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Tarsus Pharmaceuticals (TARS) and Abbott Laboratories (ABT)

July 20 at 2:11 AM | theglobeandmail.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Jennison Associates LLC

July 19 at 7:30 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up - Here's What Happened

July 18 at 12:03 PM | marketbeat.com

William Blair Issues Negative Forecast for TARS Earnings

July 18 at 2:41 AM | americanbankingnews.com

Tarsus Pharmaceuticals: Making Big Strides

July 17, 2025 | seekingalpha.com

William Blair Issues Pessimistic Estimate for TARS Earnings

July 16, 2025 | marketbeat.com

William Blair Has Bearish Estimate for TARS FY2026 Earnings

July 16, 2025 | americanbankingnews.com

What is William Blair's Estimate for TARS FY2026 Earnings?

July 15, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Consensus PT from Analysts

July 15, 2025 | americanbankingnews.com

Tarsus Pharmaceuticals Stock Price, Quotes and Forecasts

July 13, 2025 | benzinga.com

Hot Tick Summer Is Here. Here’s What You Need to Know and How to Stay Safe

July 12, 2025 | gizmodo.comG

Grant GrossMendelsohn LLC Sells 26,143 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 12, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Analysts

July 12, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Sells 12,401 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 5, 2025 | marketbeat.com

Tarsus Pharmaceuticals Inc Ordinary Shares - Morningstar

July 2, 2025 | morningstar.comM

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Lisanti Capital Growth LLC

June 29, 2025 | marketbeat.com

Tarsus Pharmaceuticals Becomes Oversold (TARS)

June 19, 2025 | nasdaq.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

MREO, IRON, TARS, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$21.03 +0.28 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$21.07 +0.04 (+0.21%)

As of 04:44 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Disc Medicine NASDAQ:IRON

$59.38 +1.61 (+2.79%)

Closing price 07/21/2025

Extended Trading

$59.47 +0.09 (+0.15%)

As of 04:25 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Mereo BioPharma Group NASDAQ:MREO

$1.71 -0.06 (-3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$1.71 0.00 (-0.06%)

As of 04:34 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Tarsus Pharmaceuticals NASDAQ:TARS

$42.18 -1.07 (-2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$42.22 +0.05 (+0.11%)

As of 04:37 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time